FORMULATION AND DEVELOPMENT OF SUSTAINED RELEASE MATRIX TABLETS OF LORNOXICAM
Lornoxicam is a NSAID having oxicam class mainly prescribed in the treatment of osteoarthritis and rheumatoid arthritis. NSAID have the potential to relieve the pain and inflammation without the immunosuppressive and metabolic side effects associated with corticosteroids. Generally the classification of NSAID is applied to drugs that inhibit one or more steps in the metabolism of Arachidonic Acid (AA). In general, NSAID do not inhibit lipoxygenase formation or the formation of other inflammatory mediators. Due to its more biological half-life i.e. 3-5 hrs. in India, the dosage form is available in 8-16 mg, it can be increased upto 24 mg/day if necessary. The main objectives of present investigation are to confirm the drug by various analytical techniques, to study the drug excipients compatibility, to avoid the dose as well as the frequency of the dosage form and to perform the stability. The tablet can be developed with the combination of HPMC K 100M and Ethyl Cellulose as a matrix former. Lornoxicam is NSAID that has numerous functions in the body. It can be absorbed rapidly and completely from gastrointestinal track after the oral administration. Absolute bioavailability of Lornoxicam is 90-100%. No first pass effect is observed. It is found in the plasma in the unchanged form and as its hydroxylated metabolite. The hydroxylated metabolite exhibits no pharmacological activity. CYP2C3 has been shown to be the primary enzyme responsible for the biotransformation of Lornoxicam. Approximately 2/3 part of Lornoxicam is eliminated via the liver and 1/3 via the kidneys as inactive substance. Lornoxicam inhibits the production of prostaglandins by inhibiting the action of cyclooxygenase, which regulates the conversion of Arachidonic Acid to Prostaglandins. Lornoxicam mainly prescribed in the treatment of osteoarthritis and rheumatoid arthritis, and also in the management of ankylosing spondylitis, acute sciatica and low back pain.
Keywords: Lornoxicam, Sustained release, matrix.
2. Siddique S, Bose A, Khanam, J. â€œModulation of drug (metoprolol succinate) release by inclusion of hydrophobic polymer in hydrophilic matrix.â€Drug Dev Ind Pharm, 2011; 37(9):1016-1025.
3. Deore RK, Kavitha K, Tamizhmani TG. â€œPreparation and evaluation of sustained release matrix tablets of tramadol hydrochloride using glyceryl palmitostearate.â€Trop J Pharm Res, 2010; 9(3):275-281.
4. Patel K., Vyas J., Upadhyay U. Formulation and evaluation of sustained release matrix tablets of nateglinide. Journal of Drug Delivery and Therapeutics, 2015; 5(5):19-25. doi:10.22270/jddt.v5i5.1130
5. Hamdani J, Moes AJ, Amighi K. â€œDevelopment and evaluation of prolonged release pellets obtained by melt pelletization process.â€Int J Pharm,2002; 245:167-177.
6. Jannin V, Cuppok Y. â€œHot-melt coating with lipid excipient.â€Int J Pharm, 2013; 457:480-487.
7. Dwivedi C., Rao S., Roy A., Saraf S., Kulsum U., Verma N., Pradhan D. Formulation and characterization of metformin hydrochloride sustained release matrix tablet containing Cassia tora mucilage. Journal of Drug Delivery and Therapeutics, 2017; 7(6):66-75. doi:10.22270/jddt.v7i6.1520
8. Momin S., Khan S., Ghadage D., Yadav A., Wagh A. Formulation and evaluation of bilayer tablets of propranolol hydrochloride. Journal of Drug Delivery and Therapeutics, 2017; 7(2):50-57. doi:10.22270/jddt.v7i2.1399
9. Sahoo C., Rao S., Sudhakar M. Formulation and evaluation of controlled porosity osmotic pump tablets for zidovudine and lamivudine combination using fructose as osmogen. Journal of Drug Delivery and Therapeutics, 2017; 7(4):41-50. doi:10.22270/jddt.v7i4.1465
10. Lloanusi NO, Schwartz JB. â€œThe effect of wax on compaction of microcrystalline cellulose beads made by extrusion and spheronization.â€Drug Dev Ind Pharm, 1998; 24:37-44.
11. Vinchurkar K., Mane S., Balekar N., Jain D. Formulation and evaluation of tablets containing artemether microspheres and lumefantrine. Journal of Drug Delivery and Therapeutics, 2017; 7(7):4-7. doi:10.22270/jddt.v7i7.1569
12. Sharma A., Sharma P., Darwhekar G. Formulation and evaluation of bilayer tablet of metronidazole and dicyclomine hydrochloride for treatment of irritable bowel disease. Journal of Drug Delivery and Therapeutics, 2017; 7(7):56-58. doi:10.22270/jddt.v7i7.1586
13. Julia A. Balfour, Andrew Fitton, Lee B. Barradell, Lornoxicam: A Review of its Pharmacology and Therapeutic Potential in the Management of Painful and Inflammatory Conditions, 1916; 51(4):639-657.
14. Indian Pharmacopoeia, Government of India, Ministry of health and family welfare, volume 1, published by The Indian Pharmacopoeia Comission, Gaziabad, 2014: 190.
15. The Merck Index, an encyclopedia of chemicals, drugs and biological, Fourteenth edition, published by Merck Research Laboratories: 5584.
16. Kumar GP, Battu G, Lova R, Kotha NS, Preparation and evaluation of sustained release matrix tablets of Lornoxicam using tamarind seed polysaccharide, Int. J. Pharm. Res. Dev, 2011; 2(12):89-98.
17. Reddy KR, Once daily sustained release matrix tablets of Nicorandil: Formulation and in-vitro evaluation. PharmSciTech, 2003, 4(4): E 61.
18. Yassin EI- said Hamza, Mona Hassan Aburahma, Design and in-vitro evaluation of novel sustained release matrix tablets for Lornoxicam based on the combination of hydrophilic matrix formers and basic pH- modifiers, Pharmaceutical Development and Technology, 2009; 15:139-153.
19. Garg A, Gupta MM, Taste masking and formulation development & evaluation of mouth dissolving tablets of levocetrizine dihydrochloride, Journal of Drug Delivery and Therapeutics; 2013; 3(3):123-130
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).